Results 201 to 210 of about 22,239 (295)

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3703-3715, May 2026.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Economic burden of type 2 diabetes management in France according to clinical characteristics

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4019-4032, May 2026.
Abstract Aim We sought to investigate the treatment, medication patterns, and economic burden of type 2 diabetes (T2D) in France. Materials and Methods This was a descriptive retrospective cross‐sectional study of a representative sample of adults in the national healthcare system claims database in 2022.
Bruno Guerci, Christèle Blanc‐Bisson, Eric Vicaut, Gérard De Pouvourville, Bruno Detournay, Corinne Emery, Isabelle Bureau, Taos Ihaddadene‐Salzgeber, Fleur Levrat‐Guillen, Jean‐Pierre Riveline   +9 more
wiley   +1 more source

Prognostic Impact of DPP4 Inhibitors on Systemic Drug Therapy for Advanced Kidney Cancer Patients. [PDF]

Cancer Sci
Kamada S, Kitayama S, Yamase R, Ikeda K, Sato W, Sazuka T, Takeshita H, Sakamoto S, Yano A, Horie K, Ichikawa T, Kawakami S, Inoue S.   +12 more
europepmc   +1 more source

Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4112-4120, May 2026.
ABSTRACT Aims Evogliptin, a dipeptidyl peptidase‐4 inhibitor with a glucose‐dependent mechanism of action, is widely used as a monotherapy or in combination with other agents. However, observational studies in routine clinical settings remain limited.
Jun Hwa Hong, Sung Hoon Yu, Ki‐Hyun Baek, JaeMyung Yu, Seung Jin Lee, Hyung‐Wook Kim, Kang Seo Park, Jung Han Kim, KyungWan Min, Yong Hwan Lee, Koon Soon Kim, Min Soo Song, Ji Hoon Kim, Jie‐Eun Lee, Jong Chul Won   +14 more
wiley   +1 more source

Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study. [PDF]

Clin Mol Hepatol
Jang H, Kim Y, Lim YK, Lee DH, Joo SK, Koo BK, Kim GA, Lee W, Romeo S, Kim W, Innovative Target Exploration of NAFLD (ITEN) consortium.   +10 more
europepmc   +1 more source

Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4314-4325, May 2026.
ABSTRACT Aims To compare the effects of individual SGLT2 inhibitors on preventing new‐onset proteinuria in patients with type 2 diabetes and preserved kidney function. Materials and Methods A target trial emulation was performed using commercially available databases, including health checkups and claims data, between April 1, 2014 and March 31, 2023 ...
Hiroki Nobayashi, Michihiro Satoh, Takuo Hirose, Shingo Nakayama, Yutaro Iwabe, Hideaki Hashimoto, Takahisa Murakami, Kouji Okada, Takefumi Mori, Hirohito Metoki   +9 more
wiley   +1 more source

Risk of acute pancreatitis with DPP-4 inhibitors versus SGLT2 inhibitors in medication-naïve individuals with diabetes: A target trial emulation. [PDF]

Diabetes Obes Metab
Tatewaki T, Okada A, Kimura Y, Yasunaga H.   +3 more
europepmc   +1 more source

Impact of renal function on antidiabetic drug selection in Japan: A real‐world analysis using the J‐DREAMS database

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 801-809, May 2026.
Using a large Japanese real‐world database, we examined antidiabetic drug selection in first and second therapy stratified by renal function and study period. The earlier initiation of SGLT2 inhibitors and GLP‐1 receptor agonists increased over time, particularly in second therapy, with prescribing patterns increasingly aligned across renal function ...
Masashi Kubota, Mitsuru Ohsugi, Kohjiro Ueki   +2 more
wiley   +1 more source

Cardiovascular and renal outcomes of sodium-glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes post-PCI: a meta-analysis of 14,511 patients. [PDF]

Diabetol Metab Syndr
Badran AS, Gbreel MI, Tawfik AM, Balata M.   +3 more
europepmc   +1 more source

Systematic Characterisation of GLP‐1R in Human Enteric Nervous System: Implications for GLP‐1 as a Key Regulator of Colonic Activity

Journal of Neurochemistry, Volume 170, Issue 5, May 2026.
Glucagon‐like peptide‐1 (GLP‐1) regulates glucose homeostasis, appetite and gastrointestinal motility through activation of the GLP‐1 receptor (GLP‐1R). Although central mechanisms are well established, the anatomical distribution of GLP‐1R within the human enteric nervous system (ENS) has not been fully defined.
Kiran Devi Dontamsetti, Rubina Aktar, Madusha Peiris   +2 more
wiley   +1 more source